Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

American Century’s Testani on How to Beat Concentration Risk

BY | ETF Database
1:05 pm ET 06/11/26 | 10 VIEWS
This week’s Investment Company Institute (ICI) saw industry leaders come together to take on all sorts of topics before the ETF industry, including how to navigate one of the biggest ongoing risks to portfolios, concentration risk. VettaFi recently connected with American Century Investments’ Head of ETF Product and Strategy Sandra Testani to discuss ETF strategies that can limit that risk.Key Takeaways: QGRO’s 3.5% cap for individual security weights can help the fund address concentration risk. The quality growth ETF’s approach, emphasizing factors like income, cash, and other fundamental metrics, can help it find durable names outside of the megacap firms. The ETF has returned almost 20% over the last three years, according to ETF database data. The ETF wrapper has allowed significant investment strategy innovation over the years. With its transparency, tax efficiency, and tradability, it has become a powerful portfolio building block. The American Century U.S. Quality Growth ETF (QGRO B) provides a powerful example. QGRO takes on concentration risk with its focus on quality firms. The quality growth ETF’s index screens stocks for factors like quality, income, and growth. It looks to combine a mix of stable growers and high-growth stocks. Those traits come together in a portfolio that offers growth with reduced volatility and risk.  More Thought Leadership: American Century’s Greenblath Talks Spring Corporate Bond Shifts “Unlike traditional market-cap-weighted indexes — where the top 10 holdings can make up an outsized portion of the fund — QGRO applies a fundamental lens and caps individual security weights at 3.5%,” Testani said.  Moreover, she explained, while the fund may lag when those megacaps explode, it offers “strong downside protection,” acting as ballast if those stocks tumble. That also speaks to its merits regarding concentration risk.  The strategy has returned 19.6% over the last three years with that approach. That performance has seen the ETF outperform the ETF Database Large Cap Growth Equities Category average in that time. Charging a 29 basis point fee, the strategy could prove a solid core-plus addition for investors to consider. For more news, information, and analysis, visit the Core Strategies Content Hub. VettaFi LLC (“VettaFi”) is the index provider for QGRO, for which it receives an index licensing fee. However, QGRO is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of QGRO.

More Commentary

Healthcare ETFs: From Broad Exposure to Big Breakthroughs
BY | ETF Database
5:12 am ET 06/11/26 | 56 VIEWS
Inside ASD: The Story Behind the First Autism ETF
BY | ETF Database
9:11 am ET 06/11/26 | 22 VIEWS
Oracle's Cloud Boom Bolsters the Case for OGIG ETF
BY | ETF Database
12:18 pm ET 06/11/26 | 17 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.